The acquisition strengthens Novacyt’s position in the market and supports the longer-term growth opportunity for rapid near-patient testing as well as securing key IP and expanding the product offering and core capabilities in instrument manufacturing.
The BDB Pitmans team was led by Reading-based corporate partner Philip Weaver who was assisted by associate Michelle Gorman.
Philip Weaver comments: “The BDB Pitmans corporate team is delighted to continue working with Novacyt as it looks to reinforce its strategy and take advantage of the opportunity that COVID-19 has presented the company as it addresses a drive towards rapid, decentralised testing.
“Client relationships are built on understanding their objectives and ambitions, and we’re delighted to be part of Novacyt’s growth story.”